1

Attendee Bios

Collaboration • Innovation • Inspiration

SAS | Cary, NCDecember 2–3, 2015

2

Joel W. Beetsch, PhDVice President, Global Patient Advocacy, Corporate Affairs Celgene Corporation

Joel Beetsch leads the global development and execution of a coordinated patient-focused advocacy strategy working with multiple patient, provider, payer and policy organizations to foster safe and effective solutions to health care challenges. These efforts drive the assurance that patient access to health care solutions and medical innovation are valued and advanced.

During his 15-year tenure in the biopharmaceutical industry, Beetsch has held several medical and corporate affairs positions. He has professional interests in patient-focused care coordination, health policy and the use of health information

technology. He is also one of the founding members of Project Data Sphere, a data sharing platform on which researchers can share, integrate and analyze patient-level, deidentified, phase III cancer data. Beetsch serves as a steering committee member of the Reagan-Udall Foundation Big Data for Patients initiative and is extensively engaged with the Clinical Trials Transformation Initiative efforts to connect patients and patient groups to the research and development process.

Beetsch earned his doctorate in neurobiology/biochemistry from the Boonshoft School of Medicine at Wright State University. Following his doctoral work, Beetsch was further trained in cellular physiology at the Washington University School of Medicine in St. Louis.

Monica Bertagnolli, MDChief, Division of Surgical Oncology, Brigham and Women’s Hospital Dana-Farber Cancer Institute

Robert A. BradwayChairman and Chief Executive Officer Amgen

Robert Bradway became chairman of Amgen in January 2013 and Chief Executive Officer in May 2012. He served as the company’s President and Chief Operating Officer from 2010 to 2012 and was appointed to the Amgen board of directors in October 2011. He joined the company in 2006 as Vice President of Operations Strategy, and served as Executive Vice President and Chief Financial Officer from April 2007 to May 2010.

Prior to joining Amgen, he was a managing director at Morgan Stanley in London, where he had responsibility for the firm’s banking department and corporate finance

activities in Europe. Bradway joined Morgan Stanley in New York as a health care industry investment banker in 1985 and moved to London in 1990, where he served as head of the firm’s international health care investment banking activities until assuming broader corporate finance management responsibilities.

Bradway holds a bachelor’s degree in biology from Amherst College and a master’s degree in business administration from Harvard University. He is a member of the board of directors of Norfolk Southern Corporation and serves on its audit and governance committees.

2 3

Riccardo BragliaGroup CEO Helsinn Healthcare SA

Riccardo Braglia is Helsinn Group’s CEO and Managing Director. He is also a member of Helsinn Holding’s board of directors, Switzerland, and of the executive committee for Helsinn Group’s strategic management. He is the CEO and Managing Director of Helsinn Healthcare, Switzerland, as well as of Helsinn Advanced Synthesis, Switzerland. He is a member of Helsinn Birex Pharmaceuticals’ board of directors, Ireland, and Chairman of Helsinn Therapeutics’ board of directors, US.

Braglia is a board member of Thorne Research, US, and WellnessFX.com, US. He serves on the board of directors of the Swiss-American Chamber of Commerce

and is Chairman of WS Fashion Holding, Switzerland, Lugano. Braglia is a member of the management committee of the Chamber of Commerce and Industry of Canton Ticino, Lugano.

In the last few years, Braglia has been active in charity projects in Africa, building schools for children in Ethiopia and South Sudan. He created the Nuovo Fiore in Africa Foundation to support new educational projects in this area (www.nuovofioreinafrica.org).

Braglia won the 2011 Best Entrepreneur of the Year in Italian-speaking Switzerland Award, conferred by Swiss Venture Club, as well the 2012 Ernst & Young Award for the best Swiss Entrepreneur of the Year in the High Tech/Life Sciences category. He represented Switzerland at the Ernst & Young World Entrepreneur of the Year 2013 Award.

Braglia holds a degree in business economics with specialization in industrial management from Luigi Bocconi University, Milan.

David R. Brennan Chairman’s Advisory Council, CEO Roundtable on Cancer Retired CEO of AstraZeneca

David Brennan has 38 years of experience in the pharmaceutical industry. Most recently, he was Chief Executive Officer of AstraZeneca PLC from 2006 to June 2012. He previously served as the company’s Executive Vice President of North America (2001-2006) and the Senior Vice President of Commercialization and Portfolio Management (1999-2001).

While CEO, he led a team of nine global executives and 65,000 employees with over $30 billion in sales. Brennan was a member of the AstraZeneca PLC board of directors from 2005 to 2012.

Brennan currently serves on the boards of the CEO Roundtable on Cancer Chairman’s Advisory Council, the Gettysburg College Board of Trustees, Alexion Pharmaceuticals, Insmed Pharmaceuticals and Innocoll Pharmaceuticals.

Previously, Brennan was an executive board member and Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) and an executive board member of the European Federation of Pharmaceuticals Industries and Associations (EFPIA). He was President and executive board member of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA); a member

4

and steering committee participant of the European Round Table of Industrialists (ERT); and a participant and member of the International Business Council for the World Economic Forum (WEF). He was also an advisory board member at Tsinghua University in Beijing, as well as Board Chair for the PA Region American Heart Association.

Bruce A. Chabner, MD Director of Clinical Research, Cancer Center Massachusetts General Hospital

For 45 years, Bruce Chabner has devoted himself to a career in cancer research and drug development. For 14 years, he directed the Drug Development Program and the clinical trials efforts of the National Cancer Institute, as Director of the Division of Cancer Treatment. While there, he designed, participated in and reported clinical and pharmacological studies of new agents, including maytansine, folate analogues, paclitaxel, fludarabine and Yondelis.

Seventeen years ago, Chabner moved to Harvard Medical School and the Massachusetts General Hospital, where he was Chief of the Division of Hematology/

Oncology from 1995 to 2006 and Clinical Director of the MGH Cancer Center from 1995 to 2010. For the past 11 years, he has had a leadership role in the Dana-Farber Harvard Cancer Center, as Associate Director of Clinical Sciences from 2000 to 2011, and C-director of the Translational Pharmacology and Experimental Therapeutics Program from 2000 to the present.

Chabner wrote The Principles and Practice of Cancer Chemotherapy and Biotherapy, the standard textbook on the pharmacology of anti-cancer drugs, now in its fifth edition, and co-edits the standard medical textbook on pharmacology, Goodman and Gilman’s Pharmacological Basis of Therapeutics. Many of the drugs he has studied, most particularly fludarabine, cytosine arabinoside and antifolates, remain standard agents, but his interests have turned toward the strategic and regulatory issues related to development of targeted drugs. Throughout his career Chabner has remained active as a clinician, teacher and mentor of academic physician-investigators in the cancer field.

Dan Crippen, PhDExecutive Director National Governors Association

Dan Crippen works with governors to identify and prioritize the most pressing issues facing states, and oversees the day-to-day operations of the National Governors Association (NGA). Founded in 1908, NGA is the only bipartisan organization of the nation’s governors. It promotes visionary state leadership, shares best practices and speaks with a collective voice on national policy.

Prior to his work at NGA, Crippen served as the Director of the Congressional Budget Office, supporting the Congressional budget process and providing expert analysis to guide and inform economic decision making. Since CBO, Crippen has

worked in the private and nonprofit sectors primarily on health care – including Medicaid, health IT, and health care for elderly and complex patients.

4 5

Crippen served in President Ronald Reagan’s White House as Assistant to the President and Domestic Policy Adviser and as Deputy Assistant to the President for Economic Analysis. He was also Chief Counsel for Senate Majority Leader Howard Baker.

Crippen is a trustee of America’s Promise Alliance and the Center for Health Care Strategies, and a board member of the Committee for a Responsible Federal Budget. He is a member of the MIT Center for Finance and Policy advisory board and the Peterson Center on Healthcare advisory board. He previously served on committees at Google and NASA. Crippen completed his undergraduate work at the University of South Dakota and earned a PhD and a master’s degree in public finance from Ohio State University.

Shannon DiBariChief Operating Officer and Executive Vice President US Chamber of Commerce

Thomas J. DonohuePresident and CEO US Chamber of Commerce

Since assuming his position at the US Chamber of Commerce in 1997, Thomas Donohue has built the Chamber into a lobbying and political powerhouse with expanded influence across the globe.

During his tenure, the Chamber has dramatically expanded the activities of the National Chamber Litigation Center, the Chamber’s law firm and the US Chamber of Commerce Foundation. Donohue established the US Chamber Institute for Legal Reform, which advances legal reforms in the courts, at the state and federal levels, and in elections for state attorneys general and Supreme Court judges.

Donohue has advanced the American Jobs, Growth and Opportunity Agenda, a plan that includes expanding trade and domestic energy production, rebuilding America’s infrastructure, combating new regulations, protecting intellectual property, revitalizing capital markets, and reforming entitlements and the tax system. The Chamber is a major political force in mobilizing support of pro-business candidates in races for the Senate and the House of Representatives.

Donohue also spearheaded the creation of the Campaign for Free Enterprise. A signature project of the campaign is Hiring Our Heroes, which identifies job opportunities for returning military veterans and spouses.

Previously, Donohue served as President and CEO of the American Trucking Associations and Deputy Assistant Postmaster General of the US. He earned a bachelor’s degree from St. John’s University and a master’s degree from Adelphi University. He is a 2013 recipient of the Horatio Alger Award.

6

H. Shelton Earp, MDDirector, UNC Cancer Care UNC Lineberger Comprehensive Cancer Center

Shelton Earp is the Lineberger Professor of Cancer Research, Director of UNC Cancer Care and former Director of the UNC Lineberger Comprehensive Cancer Center. In these roles, he has helped develop basic, clinical and public health research and cancer care at one of the country’s premier public universities and academic medical centers. He serves as Principal Investigator of the UNC Breast Cancer SPORE and his laboratory conducts fundamental and translational research in breast cancer and childhood leukemia. His group has discovered and studied genes involved in a range of cancers, published over 170 biomedical-research articles and been continuously funded by NIH for over 35 years. He is currently

collaborating with the UNC Chemical Biology Center in the Eshelman School of Pharmacy to develop a new, first-in-class drug targeting one of the cancer genes discovered in his lab. Inhibition of this gene may stimulate breast cancer patients’ innate immunity against their cancer.

Earp has received UNC School of Medicine teaching awards and chaired national review committees for the American Cancer Society and the National Cancer Institute. He has served as President of the American Association of Cancer Institutes, on the NCI Board of Scientific Advisors, and on the advisory boards of 10 university cancer centers. His lab is supported by NIH grants, the Breast SPORE and the Breast Cancer Research Foundation.

David FredricksonVice President, US Specialty Care, Oncology, Infectious Disease and Neuroscience AstraZeneca

Gregory Friberg, MDGlobal Product General Manager Amgen

Greg Friberg received his degree in biochemistry from Middlebury College and MD from New York Medical College. He completed his training in internal medicine at Dartmouth-Hitchcock Medical Center and in hematology and oncology at the University of Chicago Hospitals. As part of his training, he graduated from the University of Chicago Health Sciences Department Clinical Research Training Program specializing in clinical trial design and analysis. Friberg joined the faculty of the University of Chicago as part of the phase I, gastrointestinal and gynecologic oncology teams, where he served as the Principal Investigator for multiple early-phase clinical studies. He published multiple research papers and reviews, and he

was an active member of ASCO, the CALGB and the GOG.

Friberg joined Amgen in 2006 as an Associate Medical Director in Oncology Early Development. He served as the team lead for multiple early- and mid-stage programs, shepherding molecules though IND filings, into initial human studies, and onto later development. Friberg was promoted to Executive Director and group lead in 2011, serving for over three years as Therapeutic Area Head for Oncology

6 7

Early Development. In 2014, he transitioned to Oncology Global Development, serving as an area co-lead responsible for management oversight of trebananib, denosumab, blinatumomab and talimogene laherparepvec. Friberg was recently appointed as General Manager for bispecific t-cell engager platform, responsible for cross-functional clinical and commercial development of blinatumomab and AMG 330.

Jim GoodnightCEO SAS

As the CEO of SAS, the world’s leading business analytics software vendor, Jim Goodnight has led the company since its inception in 1976, overseeing an unbroken chain of revenue growth and profitability unprecedented in the industry. He is recognized globally for being a trailblazer among companies that top great workplace rankings, including being No. 1 on several country and multinational lists. Harvard Business School named Goodnight a Great American Business Leader, and he was named one of America’s 25 Most Fascinating Entrepreneurs by Inc. magazine. A champion of education reform, Goodnight sees education as critical to the success of individuals, organizations and nations.

Mary R. GrealyPresident Healthcare Leadership Council

Mary Grealy has served as President of the Healthcare Leadership Council (HLC) since 1999. The HLC is a coalition of chief executives of the nation’s leading health care companies and organizations that advocates consumer-centered health care reform, emphasizing the value of private sector innovation. It is the only health policy advocacy group that represents all sectors of the health care industry.

Grealy has led important initiatives on the uninsured, Medicare reform, improving patient safety and quality, protecting the privacy of patient medical information and reforming the medical liability laws. She testifies frequently before Congress and

federal regulatory agencies.

Prior to her tenure at HLC, Grealy served as Chief Washington Counsel for the American Hospital Association. In this role, she was responsible for the organization’s legal advocacy before Congress, as well as executive and judicial branches of government.

From 1979 to 1995, Grealy was Chief Operating Officer and Executive Counsel for the Federation of American Hospitals, where she coordinated legislative and regulatory policies, as well as lobbying activities.

Grealy has a bachelor’s degree from Michigan State University and a law degree from Duquesne University. She is a member of the board of directors of TEAMHealth and Duquesne University. She is a member of the American Health Lawyers Association and serves on the advisory boards of the David A. Winston Health Policy Fellowship, Women Business Leaders in Health and the March of Dimes Public Policy Council. Modern Healthcare has ranked her as one of the 100 Most Powerful People in Healthcare and named her to its list of the Top 25 Women in Healthcare.

8

Mimi Hancock, PhD Partner Spencer Stuart

Mimi Hancock is a member of Spencer Stuart’s Life Sciences Practice, working out of the San Francisco office. Her executive search experience has given her the opportunity to complete assignments for organizations ranging from emerging life sciences companies to multinational biotechnology, pharmaceutical and medical technology firms. She has executed searches for board members as well as senior executives in general management, R&D, a variety of commercial, finance and business development positions.

Before entering the executive search industry, Hancock served as Vice President of Operations and co-founder at Avigen, a startup gene therapy company. For two years prior, she was the Director of Cell Biology at Somatix Therapy Corporation, a publicly held company focused on gene therapy. Earlier in her career, Hancock worked at Triton Biosciences, where she conducted pioneering research on a novel therapeutic approach targeting the Her2 protein in breast and ovarian cancer (Hancock et al.; Cancer Research, 1991). She began her career in health care with Peralta Cancer Research Institute as a staff scientist, and previously served on the board of directors of Bionovo, a public company developing novel therapeutics for breast cancer and women’s health.

Hancock received her BA in biological sciences from The University of Chicago and her PhD in genetics from the University of California, Berkeley. She was a postdoctoral fellow at Stanford University and a recipient of a Damon Runyon-Walter Winchell Cancer Fund fellowship.

E. Wayne Holden, PhDPresident and Chief Executive Officer RTI International

E. Wayne Holden became RTI International’s fourth President and Chief Executive Officer in 2012. Holden is a distinguished researcher and clinical psychologist with more than 27 years of professional experience. He joined RTI as Executive Vice President of Social and Statistical Sciences in 2005, overseeing the organization’s largest unit.

Prior to joining RTI, Holden served as Vice President, Senior Vice President, and ultimately, President of the research company ORC Macro. Before joining ORC Macro in 1998, he had a successful career in academia, serving more than 10 years

in a variety of roles in the Department of Pediatrics at the University of Maryland’s School of Medicine, including as Director of Pediatric Psychology and as a tenured associate professor. Since 2006, Holden has held an appointment as an adjunct professor in the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine. He is an adjunct professor in the Department of Health Policy and Management at the University of North Carolina at Chapel Hill Gillings School of Global Public Health.

Holden is a fellow of the American Psychological Association and has authored more than 130 articles, books and book chapters on various topics in clinical child/pediatric psychology and health services research. He currently serves on the board of directors for the Research Triangle Foundation, the CEO Roundtable on Cancer and the Emily Krzyzewski Center. He is also on the Board of Advisors for the Frank Hawkins Kenan Institute of Private Enterprise and is a member of the Children’s Mental Health Network Advisory Council.

8 9

Charles Hugh-Jones, MD, FRCPChief Medical Officer Sanofi North America

Charles Hugh-Jones trained at Imperial College and as a physician at Charing Cross and Westminster Medical School in London. He completed his radiology fellowship and boards in internal medicine at the Royal Postgraduate Medical School, Hammersmith Hospital.

Hugh-Jones moved to industry in 2001, first at Schering AG/Bayer AG and subsequently at Enzon and Sanofi. He has worked in roles of increasing responsibility in R&D, medical and commercial roles. In 2012 he became Chief Medical Officer of Sanofi North America.

An active member of the Life Science Consortium, Hugh-Jones supports the design and implementation of Project Data Sphere. In 2014 he was elected a Fellow of the Royal College of Physicians of the UK.

Robert A. IngramPast Chairman and Co-Founder, CEO Roundtable on Cancer General Partner, Hatteras Venture Partners

Bob Ingram is General Partner in the firm Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies in the southeast United States.

Ingram began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles to ultimately become CEO/Chairman of Glaxo Wellcome. He co-led the merger and integration that formed GlaxoSmithKline (GSK). Upon reaching the mandatory retirement age of 60, he was asked by the board to serve as Vice Chairman Pharmaceuticals, GSK. In 2010 he became Strategic Adviser to the Chief Executive Officer at GSK.

Ingram serves as Lead Director of Valeant Pharmaceuticals International and Cree, and is Chairman of the Board of Viamet Pharmaceuticals. He is Chairman of the GlaxoSmithKline Foundation and the Research Triangle Foundation of North Carolina, and serves on the boards of Regeneron Pharmaceuticals, the James B. Hunt Jr. Institute for Educational Leadership and Policy, H. Lee Moffitt Cancer Center and Research Triangle Institute.

In addition to his professional responsibilities, Ingram was asked by former President George H.W. Bush to form and chair the CEO Roundtable on Cancer. In 2004, Ingram was awarded the Martin Luther King Jr. Legacy Award for International Service. In 2006, he was appointed by former President George W. Bush to the National Institutes of Health, National Cancer Advisory Board. Ingram received the 2014 North Carolina Award for public service, the highest civilian honor the state can bestow on an individual.

10

Fikry W. Isaac, MD, MPH, FACOEMVice President, Global Health Services, Chief Medical Officer, Health & Wellness Solutions Johnson & Johnson

Fik Isaac directs the development of health and wellness strategies, policies, guidelines and services worldwide for Johnson & Johnson. He is also the Chief Medical Officer for Johnson & Johnson’s Health & Wellness Solutions – a company offering comprehensive wellness solutions for employers, health plans and other organizations.

Isaac is a pioneer in the field of workplace health promotion and global health. He is a published author in the field and researches population health interventions using rigorous scientific methods. Isaac is a champion of prevention and health promotion

and has achieved remarkable success within Johnson & Johnson.

Isaac was asked to meet with the Office of Personnel Management and the White House to provide input to a pilot program for health and wellness in the federal workforce during US health care reform discussions. In 2013 he was the recipient of the Global Leadership in Corporate Health Award, the Donald H. Gemson Cancer Prevention and Public Policy Award from the American Cancer Society and the US Chamber of Commerce’s Leadership in Health Care Award.

Isaac received his medical degree from Ain Shams University Medical School and his master’s in public health with a concentration in occupational medicine from the Medical College of Wisconsin. He is a fellow of ACOEM, a member of the Gold Standard Task Force – CEO Roundtable on Cancer, and is the industry co-chair of the LSIF-APEC. He also serves on the boards of the Partnership for Prevention, the Global Business Group on Health and the Health Enhancement Research Organization (HERO).

Stephen L. Kindred, MD Assistant Vice President for Corporate Medical State Farm

Stephen Kindred works at the State Farm corporate headquarters in Bloomington, IL. He joined State Farm as an Assistant Medical Director in 1990, was promoted to Medical Director in 1994 and assumed his current position in 1998. A native of Illinois, Kindred received a bachelor’s degree from Wabash College, and a doctorate from the University of Illinois College of Medicine, Peoria. He served his residency in internal medicine at the Mayo Clinic in Rochester, MN. Kindred received his Master of Public Health degree in 2006 from The Medical College of Wisconsin. He is a diplomat of the American Board of Internal Medicine and a member of the American

College of Physicians, the Illinois State Medical Association and the McLean County Medical Society.

Robert LaCazeSenior Vice President, Global Head of Oncology TA Bayer HealthCare Pharmaceuticals

10 11

Kenneth B. LeeGeneral Partner Hatteras Venture Partners

Ken Lee is a general partner of Hatteras Venture Partners, a North Carolina-based venture firm founded in 2000. With Hatteras since 2003, he is involved in deal sourcing, investment decisions and implementing exit strategies.

Lee began his 29 year career with Ernst & Young in 1972 in the San Francisco office. He got his start in biotech as part of the first audit team of Genentech in 1976. He was also on the team that took Genentech public, an industry milestone. Eventually, Lee rose to become Ernst & Young’s National and International Life Sciences Practice Leader. As co-founder of the firm’s national life sciences practice, he advised

numerous high-profile life science companies with their initial public offerings, mergers and acquisitions, and strategic financings. Among others, these included: Affymax, Affymetrix, Applied ImmuneSciences, Chiron, Circadian, Genentech, Heartport, Systemix, ALZA and Collagen. He was also active in advising and collaborating with life sciences investment firms around the world.

Lee is a nationally-recognized financial matters expert and has served on seven public company boards, including Abgenix, CV Therapeutics and OSI Pharmaceuticals. He serves as Chairman of the Board of Clinipace (privately held), and he previously served as Chairman of the Inspire Pharmaceuticals board until the company’s sale to Merck in 2011. Lee currently serves on the boards of Pozen Inc. (POZN) and BioCryst Pharmaceuticals (BCRX). He has chaired boards of directors, audit committees, finance committees, compensation committees and is the Lead Independent Director of Pozen.

Joseph Leveque, MDChief Medical Officer EMD Serono

Joseph Leveque serves as Chief Medical Officer and Senior Vice President at EMD Serono, where he is committed to serving patients suffering with grievous illnesses by developing and implementing medical programs that accelerate the assimilation and translation of knowledge and key insights into clinical practice.

Prior to joining EMD Serono, Leveque was the Vice President and Head of US Medical Oncology (USMO) at Bristol-Myers Squibb. Under his leadership, the USMO team supported the successful launch of the company’s first two immuno-oncology therapeutics in three indications. The USMO team was recognized by the US

Oncology Network with its LEAD award, which honors companies for their commitment to the research and clinical education that effectively brings innovative medicines to cancer patients.

Prior to joining BMS, Leveque was the Vice President of Medical and Scientific Affairs at Onyx Pharmaceuticals when the company was developing and commercializing a next-generation proteasome inhibitor for the treatment of multiple myeloma. While at Onyx, he was recognized by the Multiple Myeloma Research Foundation as one of the top 15 innovators in multiple myeloma over the last 15 years.

Leveque also served as Vice President of Medical and Scientific Affairs at Cephalon Oncology and as Medical Director at Amgen.

12

Leveque received his undergraduate degree from Santa Clara University; his Medical Doctorate from the University of Texas School of Medicine in Houston; and his MBA from the Wharton School of the University of Pennsylvania. Leveque completed his postgraduate medical training in internal medicine at the UCLA Cedars-Sinai Medical Center.

Douglas R. Lowy, MDActing Director National Cancer Institute, NIH

Anne LubenowSpecial Assistant to the Director National Cancer Institute, NIH

Francois MaisonrougeSenior Managing Director Evercore Partners

As a Senior Managing Director in Evercore Partners’ advisory business, Maisonrouge was involved in advising Shire in its defense across from Abbvie; AstraZeneca in its defense across from Pfizer; Sun Pharmaceutical Industries on its acquisition of Ranbaxy Laboratories; Aptalis on its sale to Forest Pharmaceuticals; Bristol-Myers Squibb on its acquisition of Amylin and sale of half of its interest in Amylin to AstraZeneca; Fenwal on its sale to Fresenius; Sage Products on its sale to Madison Dearborn; Terumo on its acquisition of CaridianBCT; Sanofi on its acquisition of Genzyme and of Merck’s 50 percent stake in Merial; Movetis on its sale to Shire; TPG on its acquisition of IMS Health; and Wyeth on its combination with Pfizer.

Prior to joining Evercore, Maisonrouge was a Managing Director and Chairman of Life Sciences at Credit Suisse, where he worked extensively in the fields of pharmaceuticals, specialty pharmaceuticals, biotechnology and medical technology. At Credit Suisse, he was responsible for leading the firm’s relationships with large health care clients such as Johnson & Johnson, Schering-Plough, Wyeth, GlaxoSmithKline, Roche and Teva, most notably in executing mergers and acquisitions and capital raising transactions.

Maisonrouge has an MS in engineering from Ecole Centrale de Lyon and an MBA from Harvard Business School. He is a member of the board of advisers of the Harvard Business School Health Care Initiative, and the Director of the Pasteur Foundation. In 2014, Maisonrouge was awarded the rank of Chevalier de la Légion d’honneur.

12 13

Ann Murphy, PhD Publisher and Managing Editor The Oncologist, STEM CELLS and STEM CELLS Translational Medicine

Ann Murphy has managed STEM CELLS, the oldest journal in the area of stem cells and regenerative medicine, for 33 years. She maintains the journal’s excellence as it exponentially expands its size and scope as a top-tier global peer-reviewed journal devoted to stem cell biology.

STEM CELLS Translational Medicine (SCTM), now in its fourth volume, is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

Murphy is also the Founding Managing Editor of The Oncologist journal, a monthly international peer-reviewed journal for physicians devoted to cancer patient care, and has guided and nurtured its growth and development over its 20-year history. She has also led The Oncologist Continuing Medical Education Program from its inception and is Board Designate of the Society for Translational Oncology (STO), accredited by the ACCME.

Murphy played a salient role when the senior editors of The Oncologist founded STO in 2000 to fill the gap between discovery of new oncology treatments and their global translation into oncology practice.

Murphy holds a PhD with distinction in literature from New York University. She serves on the Board of Visitors of the UNC Lineberger Comprehensive Cancer Center. She is a published authority on the Irish literary renaissance and the biographer of the Irish playwright and poet Padraic Colum.

Martin J. Murphy Jr., DMedSc, PhD, FASCOChief Executive Officer and Co-Founder, CEO Roundtable on Cancer Chairman of the Board and Chief Executive Officer, AlphaMed Consulting

Martin J. Murphy is founding Chairman and Chief Executive Officer of AlphaMed Consulting, which provides strategic support for cancer drug development programs in academic centers, global pharmaceutical and biotechnology companies. Murphy is a member of the National Cancer Policy Forum of the National Academy of Medicine of the National Academy of Sciences; a Director of the Foundation for the National Institutes of Health; and charter member and Vice Chairman of C-Change, also founded by former President George H. W. Bush and former first lady Barbara Bush. Murphy is a Fellow of the American Society of Clinical Oncology, and the founding Executive Editor of The Oncologist, STEM CELLS and

STEM CELLS Translational Medicine. He is a co-founder of the Society for Translational Oncology; a member of the Scientific Advisory Board of Hatteras Venture Partners; a charter member of the International Advisory Board of the VU University Medical Imaging Center; a charter member of Queen’s University Belfast School of Medicine International Review Board; Chairman Emeritus of the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO); convener of ACT-China; and a steering committee member and senior consultant to the Chinese Society of Clinical Oncology.

14

Sharyl Nass, PhDDirector of the Board on Health Care Services Director of the National Cancer Policy Forum Institute of Medicine (IOM) at the National Academies of Sciences, Engineering and Medicine

For more than 15 years at the IOM, Sharyl Nass has worked on a broad range of topics that includes the quality of care, clinical trials, oversight of health research, development and assessment of medical technologies, and strategies for large-scale biomedical science. The Board on Health Care Services addresses the organization, financing, effectiveness, workforce and delivery of health care to ensure the best possible care for all patients. The National Cancer Policy Forum examines policy issues pertaining to the entire continuum of cancer research and care.

Nass has a PhD in cell and tumor biology from Georgetown University and undertook postdoctoral training at the Johns Hopkins University School of Medicine. She also holds a BS in genetics from the University of Wisconsin-Madison, and she studied developmental genetics and molecular biology at the Max Planck Institute in Germany under a fellowship from the Heinrich Hertz-Stiftung Foundation. She was the 2007 recipient of the Cecil Award for Excellence in Health Policy Research, the 2010 recipient of a Distinguished Service Award from the National Academies, and the 2012 recipient of the IOM staff team achievement award (as the team leader).

Judy O’HaganCo-Chair, CEO Cancer Gold Standard Task Force Vice President, Human Resources, Sanofi US

Since September 2007 Judy O’Hagan has been a Human Resources Vice President for Sanofi US, where her scope of responsibilities includes North America pharmaceuticals, global services, consumer health care and R&D. At Sanofi, O’Hagan serves as the Steering Committee Chairperson for WISE (Women Inspiring Sanofi Excellence) and is a member of the 2012 Healthcare Businesswomen’s Association Advisory Board. She also serves as the Co-Chair of the CEO Cancer Gold Standard Task Force for the CEO Roundtable on Cancer.

In her community, O’Hagan serves as Vice President of the board of directors for Jersey Battered Women’s Services. She is also the Sanofi Executive Sponsor for the Corporate Work Study Program with the Cristo Rey Network in Newark, NJ, and is actively involved in the development and college placement support of Cristo Rey students. O’Hagan is a member of the Advisory Council for Marquette University’s College of Arts and Sciences, where she is also active in development and recruitment.

O’Hagan began her career in the pharmaceutical industry in 1978 as an HR professional at Sandoz Pharmaceuticals Corporation, and in 1996, when Sandoz and Ciba-Geigy merged to form Novartis Pharmaceuticals, she was appointed Executive Director for the Organization and Leadership Development function. In 1999, she was appointed Vice President of Human Resources for the Commercial Division of Novartis.

14 15

Art PappasManaging Partner Pappas Ventures

Art Pappas has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. He founded Pappas Ventures in 1994. The firm manages over $350 million, and has guided the launch and development of over 55 life sciences companies. The firm also manages the Chiesi Venture Fund, which invests in companies developing medicines for rare and orphan diseases.

Pappas currently serves as a director of Afferent Pharmaceuticals, Aura Biosciences and CoLucid Pharmaceuticals, for which he is Chairman and served as the founding

CEO. Prior to founding Pappas Ventures, he held senior-level leadership positions at several multinational pharmaceutical companies including Glaxo Holdings, where he was chief executive responsible for international operations, Abbott International, and Merrell Dow Pharmaceuticals and the Dow Chemical Company. He previously served on the boards of Chimerix, Quintiles, TYRX (acquired by Medtronic in 2014), Syntonix Pharmaceuticals (acquired by Biogen IDEC in 2007), LEAD Therapeutics (acquired by BioMarin in 2010), CardioDx, and Embrex, which was acquired by Pfizer. He also served as a board observer at Plexxikon, which was sold to Daiichi Sankyo in 2011.

Pappas serves on the boards of the NVCA, the NC Biotechnology Center, the Medical University of South Carolina Foundation for Research Development, The Wistar Institute and the Duke Cancer Institute. He is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division. Pappas received a BS in biology from Ohio State University and an MBA in finance from Xavier University.

Thomas PikeChief Executive Officer Quintiles

Philip D. Porter, JD, MEd Of Counsel Hogan Lovells US

Philip Porter has assisted the CEO Roundtable on Cancer’s Life Sciences Consortium with preparation of the START Clauses, whose purpose is to accelerate completion of clinical trial agreements. He has also assisted Project Data Sphere with formulation of its Data Sharing Agreement and Online Service User Agreement, and with structuring its operations consistent with laws applicable to web-based services.

16

Chandra Ramanathan, PhD, MBASenior Director, Innovation Strategy and Global Lead, External Innovation Bayer AG

Chandra Ramanathan focuses on new sourcing models (open innovation), venture capital strategy and engagement strategies at global innovation hot spots. In addition, he is responsible for furthering development and integration of external innovation activities throughout Bayer (HealthCare and Crop Science) to advance its innovation capabilities.

Prior to this role, Ramanathan was the head of pipeline marketing and the global launch team leader of Copanlisib. He was the Co-Chair of the value strategy team to ensure customer insights (physicians, payers and patients) are incorporated

as part of development strategies. He also developed the commercial foundation for companion diagnostics development.

Before joining Bayer, Ramanathan worked in different roles at Wyeth (Pfizer) and Bristol-Myers Squibb, including as global brand team leader, licensing/business development, neuroscience strategy, drug discovery and applied genomics.

Ramanathan has worked across the pharmaceutical product development and commercialization spectrum for more than 19 years. He has broad commercial and research backgrounds, with an MBA from the Columbia Business School, a PhD in genomics/bioinformatics and a BS in pharmacy.

Matthew Ros Vice President and Chief Operating Officer, Oncology Global Strategic Business Unit Sanofi

Matt Ros leads Sanofi’s global commercial and medical affairs organization for its $1.6 billion oncology franchise. He serves as a member of the oncology leadership team and actively contributes to the oversight of the company’s oncology clinical development, research, regulatory and commercial product development strategies.

Prior to joining Sanofi, Ros served as Senior Vice President Commercial Operations of ARIAD Pharmaceuticals. Earlier in his career, from 1990 to 2007, he held numerous sales, marketing and franchise leadership roles and contributed to a multitude of successful product launches at Bristol-Myers Squibb Oncology.

From 2004 to 2012 Ros served as a board of trustees member for CancerCARE Inc., the leading national organization dedicated to providing free, professional support services – including counseling, support groups, educational workshops, publications and financial assistance – to anyone affected by cancer.

He holds a Bachelor of Science in business administration from The State University of New York.

16 17

Mace L. Rothenberg, MDCo-Chair, Life Sciences Consortium Task Force Senior Vice President of Clinical Development and Medical Affairs, and Chief Medical Officer, Pfizer Oncology

Mace L. Rothenberg is a member of Pfizer Oncology’s leadership team and is responsible for overseeing clinical research and development activities, as well as post-marketing evaluation and monitoring for all oncology products. He is a member of Pfizer’s Portfolio Strategy and Investment Committee and Senior Leadership Council. Rothenberg co-chairs the Life Sciences Consortium of the CEO Roundtable on Cancer and serves on the NYU School of Medicine Alumni Board of Governors.

Rothenberg came to Pfizer in 2008 after 25 years in academia at the University of Texas Health Science Center – San Antonio and Vanderbilt University, where he

focused on early stage drug development, clinical trial design and the coordinated laboratory-clinical evaluation of new therapies for gastrointestinal cancers. He chaired the pivotal clinical trials that led to FDA approval of irinotecan (CPT-11, Camptosar®) and oxaliplatin (Eloxatin®) for colorectal cancer, and a key trial used as the basis for approval of gemcitabine (Gemzar®) for pancreatic cancer. At Pfizer, Rothenberg has led CDMA in the successful development of four new FDA-approved cancer drugs: crizotinib (Xalkori®) for ALK+ non-small cell lung cancer, axitinib (Inlyta®) for renal cell carcinoma, bosutinib (Bosulif®) for Ph+ chronic myelogenous leukemia, and palbociclib (Ibrance®) for ER+ advanced breast cancer.

Rothenberg is the recipient of the American Cancer Society’s Lane W. Adams Quality of Life Award and the American Society of Clinical Oncology’s Statesman Award. He is a Fellow of the American College of Physicians and the American Society of Clinical Oncology. Rothenberg received his BA from the University of Pennsylvania, his MD from the New York University School of Medicine, his post-graduate training in internal medicine at Vanderbilt University and his medical oncology training at the National Cancer Institute.

Eric H. Rubin, MDVice President and Therapeutic Area Head Oncology Early Development Merck Research Laboratories

Eric H. Rubin has focused on cancer drug development for over 20 years, initially as a faculty member at the Dana-Farber Cancer Institute, then as a senior leader of the Cancer Institute of New Jersey. His research efforts focused on mechanisms of resistance to DNA topoisomerase-targeting drugs, and his laboratory cloned a novel topoisomerase I- and p53-interacting tumor suppressor gene, TOPORS. In 2008, Rubin was recruited to Merck as Vice President of Oncology Clinical Research. He led the development of the anti-PD-1 antibody pembrolizumab, which was the first anti-PD-1 therapy approved in the US, and in the identification of the significant

activity of this antibody across several additional cancer types. In his current role he oversees oncology early development and translational research activities at Merck.

Rubin has written over 100 original, peer-reviewed publications and book chapters related to oncology translational research, clinical trials and drug development. He has served frequently as a member of National Cancer Institute and American Cancer Society study sections, as well as on program committees for

18

the American Association of Cancer Research and the American Society of Clinical Oncology. In addition, he serves on several editorial boards, and is a deputy editor for Clinical Cancer Research. Rubin obtained his medical degree from the University of South Florida and completed residency at Yale-New Haven Hospital.

Charles A. Sanders, MD Executive Chairman, Foundation for the National Institute of Health (FNIH) Retired Chairman and CEO, Glaxo

Charles Sanders is retired from Glaxo Inc., where he served as Chief Executive Officer from 1989 through 1994 and Chairman of the Board from 1992 through 1995. Prior to joining Glaxo, Sanders spent eight years with Squibb Corporation, where he held a number of positions, including Vice Chairman. Previously, Sanders was General Director of Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. He is currently a member of the Institute of Medicine of the National Academy of Sciences, Chairman Emeritus of Project HOPE and Chairman of the Foundation for the National Institutes of Health. He is also past Chairman of the UNC

Health Care System. Additionally, he serves on the boards of several publicly traded companies. He earned his MD from the University of Texas Southwestern Medical School.

Daniel J. Sargent, PhDRalph S. and Beverly E. Caulkins Professor of Cancer Research Mayo Clinic

In addition to his academic position at the Mayo Clinic, Daniel Sargent is the Group Statistician for the Alliance for Clinical Trials in Oncology, Director of Biostatistics Shared Resource at the Mayo Clinic Comprehensive Cancer Center, and Section Head for the Section of Cancer Center Statistics at Mayo Clinic. Sargent co-chaired a joint NCI-EORTC committee on methodology for tumor marker studies, was a member of the FDA panel on endpoints for colon cancer clinical trials, and from 2007 to 2013 was a member of the US NCI Clinical Trials Advisory Committee, which oversees all NCI-funded cancer clinical trials in the United States. He presently serves

on the Clinical Trial Design Task Force of the NCI’s Investigational Drug Steering Committee. He has published extensively in colorectal cancer treatment, optimal clinical trial endpoints, and prognostic and predictive biomarkers. He leads multiple international data pooling and analysis consortia, including ACCENT in adjuvant colon cancer and FLASH in follicular lymphoma, as well as the prospective IDEA international pooled analysis testing the duration of therapy in Stage III colon cancer. He has published over 290 peer-reviewed manuscripts, book chapters, editorials and letters.

18 19

Howard I. Scher, MD Chief, Genitourinary Oncology Service Memorial Sloan Kettering Cancer Center

Howard Scher is Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC), Professor of Medicine at the Weill Cornell Medical College, and the D. Wayne Calloway Chair in Urologic Oncology. Scher’s research is focused on the codevelopment of targeted therapies and blood- and tissue-based biomarkers, such as circulating tumor cells, that can be used to accelerate drug development and guide the choice of treatment for an individual patient based on the biology of his disease. Accordingly, he led the international effort to standardize the design and analysis of phase II prostate cancer trials and has

helped elucidate key molecular and genetic features of prostate cancer growth and progression. He has translated these novel insights into the clinic by leading early phase and phase III registration trials of abiraterone acetate and enzalutamide, which are now FDA approved. Scher serves as the Principal Investigator of the NIH Specialized Program of Research Excellence (SPORE) in Prostate Cancer at MSKCC, the Department of Defense-sponsored Prostate Cancer Clinical Trials Consortium and Biomarker Validation Coordinating Center. He received the 2015 AACR Team Science Award for his multidisciplinary work developing AR inhibitors.

Chen SchorCEO Synta Pharmaceuticals

Chen Schor is President and Chief Executive Officer of Synta Pharmaceuticals and a member of the company’s board of directors. He has over 15 years of leadership experience in biotechnology, medical devices, business development and private equity. Prior to joining Synta, he served as Vice President of Global Branded Products Business Development and Pipeline Management at Teva Pharmaceuticals, and at leadership positions in several emerging private and public companies. Over his career, Schor has led licensing and M&A transactions valued at over $8 billion with GSK, Amgen, Pfizer, Merck KGaA, OncoGeneX and other companies. As a partner at

Yozma Venture Capital, he led the foundation and growth of multiple therapeutic companies from inception to significant commercial success and exit. Schor holds an MBA, a BA in biology and a BA in economics, and is a Certified Public Accountant (CPA).

20

Mike Sokol, MDVice President, Employee Wellness Chief Wellness Officer Sanofi

Mike Sokol is responsible for designing, implementing and measuring a fully integrated health and wellness strategy for the employees and their families at Sanofi. The goal is to create a culture of health by promoting a healthy work environment and providing employees with the resources they need to manage their health along the entire health care continuum.

Most recently, Sokol served as the Global Corporate Medical Director at Merck, where he developed the company’s first comprehensive incentives-based health and wellness initiative. Prior to Merck, he provided consultative support to large

employers and health plans, focusing on population health and disease management, quality improvement and value-based insurance design at Medco Health Solutions and GlaxoSmithKline. He also conducted research demonstrating the clinical and financial benefits of improving medication adherence.

Sokol received his undergraduate degree from Ursinus College and his medical degree from Jefferson Medical College. He completed his residency in preventive medicine at the University of Maryland Medical System, where he also received his Master of Science degree from the Department of Epidemiology and Preventive Medicine. Sokol is board-certified in public health and general preventive medicine and is a Fellow of the American College of Preventive Medicine. He also holds an academic appointment in the Department of Preventive Medicine at the Mount Sinai School of Medicine in New York.

Sokol sits on several institute boards at the National Business Group on Health, serves on the editorial board of the journal Population Health Management and has published several original manuscripts in peer-reviewed medical journals.

Gail Stephens Senior Director, Health and Life Sciences R&D SAS

Leading collaborative teams that deliver quality software has been Gail Stephens’ mission for the past 30 years at SAS. By combining two of her greatest passions – the advancement of science and world-class SAS Analytics – she helps customers harness data’s hidden intelligence to make the world a better place.

Stephens is the executive champion of health and life sciences at SAS. In this capacity she manages R&D organizations, consults with customers on data-driven initiatives, and evangelizes how SAS software can deliver insights that transform organizations. One of her projects is the groundbreaking collaboration Project Data

Sphere, which is a first-of-its-kind platform that makes historical data and analytics broadly accessible to those seeking to advance cancer treatment research. The project integrates SAS Visual Analytics and health and life sciences software.

Prior to leading SAS’ health and life science initiatives, Stephens developed graphical user interfaces (GUIs) and managed teams that developed some of the earliest GUIs at SAS. She also spent many years leading the overall BI R&D efforts at SAS, an experience that provided unique insights into streamlining BI software within the health and life sciences projects she oversees today.

20 21

Stephens is a North Carolina native and holds a bachelor’s degree in computer science from North Carolina State University in Raleigh, where she has served on the Strategic Advisory Board for the computer science department. Additionally, Stephens serves on the board of directors for The North Carolina Healthcare Information and Communications Alliance.

Bruno Strigini, MS, PhD, MBAPresident, Oncology Novartis

Bruno Strigini is President of Novartis Oncology, a pharmaceutical business unit of Novartis supported by more than 11,000 employees in 85 countries with nine key marketed products and one of the leading pipelines in the industry.

Before joining Novartis in 2014, he was President of MSD for Europe and Canada (Merck & Co. Inc. in the US and Canada). Previous roles at Schering-Plough, UCB-Celltech and SmithKline Beecham have included President of International Operations, President of Japan and Asia-Pacific, and Head of Global Marketing and Business Development, as well as other senior leadership positions.

Strigini holds an MBA from IMD, Lausanne (Switzerland), a doctorate of pharmacy from the University of Montpellier (France), and a master’s degree in microbiology from Heriot-Watt University (UK). He is a member of the Académie Nationale de Pharmacie in France. In 2014, he was awarded Doctor Honoris Causa from Menéndez Pelayo International University (Spain).

Zhen Su, MDVice President of Medical Oncology EMD Serono

Zhen Su leads medical strategy for EMD Serono. A physician executive with more than 15 years of experience, Su has strong clinical expertise in oncology, immuno-oncology and urology.

He has held positions in academic and pharmaceutical medicine, including general management, clinical development, medical affairs and business development. Prior to EMD Serono, Su served as Associate Vice President and Global Head of Jevtana (cabazitaxel) at Sanofi. Prior to joining the industry, Su held several academic positions, including Assistant Professor of Surgery at Duke University, where he also

received his fellowship in oncology.

Su has deep ties to the oncology community, having worked with leading oncologists at organizations across the country. He earned his medical doctorate degree from the Technical University of Dresden, Germany, and completed his MBA training at the University of Toronto.

22

Chris H. Takimoto, MD, PhDVice President Head of Experimental Medicine, Early Development, Oncology Therapeutic Area Janssen

Chris H. Takimoto earned a BS degree in chemistry from Stanford University, and a PhD in pharmacology and MD from Yale University. After finishing residency training in internal medicine at the University of California, San Francisco, he completed fellowships in medical oncology at the National Cancer Institute and in clinical pharmacology at the Uniformed Services University of the Health Sciences.

Takimoto then served as a senior investigator in the developmental therapeutics department in the medicine branch at the National Cancer Institute and as an assistant professor of medicine in the division of clinical pharmacology at the

Uniformed Services University. In 2000, he moved to the University of Texas Health Science Center at San Antonio as an associate professor of medicine in the division of medical oncology. In 2004, he became the Director of Pharmacology at the Institute for Drug Development at the Cancer Therapy and Research Center, where he was also the Zachry Chair for Translational Research.

In 2007, he became one of the founding members of South Texas Accelerated Research Therapeutics (START), an independent oncology clinical research center dedicated to early development trials. In 2008, Takimoto was recruited to Johnson & Johnson, where he is Vice President and head of Experimental Medicine, Early Development in the Oncology Therapeutic Area at Janssen R&D.

Takimoto’s research interests include the pharmacology of new anti-cancer agents in clinical development, oncology drug development, pharmacokinetics and pharmacodynamics, phase I clinical trials, and novel treatments for gastrointestinal malignancies.

Elizabeth Thompson President and Chief Executive Officer C-Change

Liz Thompson is well-known for her collaborative work in the cancer space. Today, as the President and CEO of C-Change, an organization focused on strategic issues in cancer and convening thought leaders to drive change, Thompson is more optimistic than ever before about the exciting advances in science and the opportunities to bring together the best and brightest to translate those discoveries to real patient outcomes. While her work and contributions to change the research, political and patient support landscapes stand on their own merits, she is quick to highlight that the she has been humbled and honored to serve with and make those

accomplishments because of the tremendous efforts of thoughtful and generous board members, brilliant staff, and engaged and committed volunteers galvanized to make an extraordinary difference in the lives of those diagnosed with and living with cancer. She has worked on programs and advocacy in 50 countries around the world.

22 23

Ann Vickery Of Counsel Hogan Lovells US

Ann Vickery is Of Counsel in Hogan Lovells’ Washington, DC, office. Before retiring from the partnership at the end of 2012, she was active in the firm’s health practice, which she led as practice director from 1991 to 2010. Vickery has represented manufacturers, associations and providers of various health care products and services with respect to a wide range of health regulatory issues. She continues to counsel clients occasionally regarding the impact of federal laws, regulation and policies on their businesses, with a particular emphasis on Medicare and Medicaid. Vickery has also been active in the firm’s management, serving two three-year terms

on the Executive Committee of Hogan and Hartson and as Managing Partner of its Washington office.

Christopher A. ViehbacherChairman, CEO Roundtable on Cancer Managing Partner, Gurnet Point Capital

Chris Viehbacher is the Managing Partner of Gurnet Point Capital, a Boston-based investment fund associated with the Bertarelli family with a $2 billion capital allocation. He is also a member of the board of PureTech Health; the Chairman of Vedanta, a PureTech portfolio company; and a member of the board of trustees of Northeastern University.

Viehbacher is the former CEO and member of the board of directors of Sanofi and the Chairman of the Board of Genzyme. Prior to joining Sanofi, Viehbacher spent 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the US as

President of GSK North America. He was a member of the board of directors of GSK plc in London and Co-President of GSK’s Portfolio Management Board. Viehbacher began his career with PwC after graduating with a degree in commerce from Queen’s University in Canada.

Viehbacher has been a strong advocate for the health care industry. He served as Co-Chair with Bill Gates for the CEO Roundtable on Neglected Diseases. At the World Economic Forum, he served as Chair of the Health Governors and Co-Chair of an initiative to create a Global Charter for Healthy Living. His other advocacy roles have included Chairman of the Board of the Pharmaceutical Research and Manufacturers of America, President of the European Federation of Pharmaceutical Industries and Associations, and member of the International Business Council. Viehbacher has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide and France’s highest civilian honor, the Legion d’Honneur.

Anne C. WhitakerExecutive Vice President and Company Group Chairman Valeant

24

Liz Zhou, MDDirector of Evidence Based Medicine Sanofi

Liz Zhou is keen on exploring innovative methods for medical insight and evidence generation. She is a strong believer in using real-world data and other novel data sources to accelerate clinical research. Zhou helped to build strategies on enhancing use of the data on the Project Data Sphere (PDS) platform and led the successful launch of PDS’ first research challenge – Prostate Cancer DREAM Challenge in 2015.

Zhou has held various positions in the commercial organization of Sanofi before she joined medical affairs. She has experience in numerous therapeutic areas such as cardiovascular, diabetes, immunology and oncology. Before Zhou joined Sanofi, she

held management positions in analytical and strategic consulting. She is an OB/GYN by training and holds a master’s degree in biostatistics.

Helmut ZodlVice President and Chief Financial Officer Worldwide Services Lenovo

Since spring of 2015 Helmut Zodl has served as the Chief Financial Officer of Lenovo’s Worldwide Services Business, helping grow Lenovo Services around the globe. Zodl has held several senior financial positions, including Lenovo’s Group Controller role. He has served as CFO for Asia Pacific as well as the Americas Group and the Worldwide Enterprise Group. Zodl has been financial lead for a number of Lenovo’s major acquisitions (IBM, NEC etc.), and throughout 2014 he served as Chief Operating Officer of Lenovo’s Brazil business. He is part of Lenovo’s Global Leadership Team (GLT).

24 25

CEO Roundtable on Cancer Staff

John N. Dornan Jr.Executive Director CEO Roundtable on Cancer

John N. Dornan Jr. is the Executive Director of the CEO Roundtable on Cancer, a nonprofit organization of cancer-fighting CEOs dedicated to eliminating cancer as a public health threat. Dornan provides administrative oversight to the group’s initiatives, including the CEO Cancer Gold StandardTM workplace accreditation program, which recognizes employers who provide state-of-the-art preventive care, wellness support and cancer treatment, and the Life Sciences Consortium, which encourages researchers to work collaboratively to accelerate the discovery and development of new therapies for cancer patients. Dornan also serves as Chief

Operating Officer of Project Data Sphere LLC, an independent initiative of the Life Sciences Consortium. The Project Data Sphere® platform provides one place where the research community can broadly share, integrate and analyze patient-level, comparator-arm data from academic and industry phase III cancer clinical trials.

Dornan formerly headed corporate public reactions for SAS, the world’s largest privately held software company, and served as Vice President of Trone, a mid-Atlantic regional advertising and public relations agency, where he specialized in communications related to corporate mergers and acquisitions. He also held marketing and communications positions with Healthsource North Carolina prior to its acquisition by Cigna. He began his career in North Carolina’s Department of Health and Human Services, where he provided outreach and communications services for the state’s welfare reform efforts and programs for children and families, including the nationally renowned Smart Start early childhood initiative created by Gov. James B. Hunt Jr.

Deborah D. DionCommunications Manager CEO Roundtable on Cancer

Deborah Dion is the Communications Manager for the CEO Roundtable on Cancer, a nonprofit organization comprised of CEOs who are dedicated to eliminating cancer as a public health threat. Dion provides strategic communications support to the group’s initiatives, including the CEO Cancer Gold StandardTM and the Life Sciences Consortium. A communications professional with more than 10 years of experience, Dion joined the CEO Roundtable in June 2015. She was previously a Corporate Communications Specialist for First Citizens Bank, responsible for web content strategy and development. Prior to joining First Citizens, Dion was a

Communications Specialist for SRA International (formerly Constella Group), specializing in corporate and marketing communications, social media and events management. She began her career in communications with the North Carolina Auto Dealers Association, where she coordinated communications for membership, online presence and legislative advocacy. Dion is a graduate of East Carolina University and the School of Communication Arts.

26

Therese M. MartinProject Manager CEO Roundtable on Cancer

Therese Martin serves as Project Manager for the CEO Roundtable on Cancer, a nonprofit organization comprised of CEOs dedicated to eliminating cancer as a public health threat. Her responsibilities include providing assistance to employers interested in adopting the CEO Cancer Gold StandardTM, a workplace accreditation program that encourages and recognizes the commitment of organizations that take concrete actions to address cancer in their workplaces. Martin is also responsible for managing program data and providing general support to CEO Roundtable on Cancer initiatives.

Prior to joining the CEO Roundtable in 2011, Martin worked as a project manager in a wide range of industries, including the military, software development, retail and nonprofit sectors. She is a graduate of the United States Air Force Academy, and earned her MBA in contracts and acquisition from Western New England College.

26 27